Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia

被引:0
|
作者
Yun, Ji Hyun [1 ]
Chang, Euijin [2 ]
Bae, Seongman [2 ,3 ]
Jung, Jiwon [2 ]
Kim, Min Jae [2 ]
Chong, Yong Pil [2 ]
Kim, Sung-Han [2 ]
Choi, Sang-Ho [2 ]
Lee, Sang-Oh [2 ]
Kim, Yang Soo [2 ,3 ]
机构
[1] Konkuk Univ, Sch Med, Dept Internal Med, Div Infect Dis,Med Ctr, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Div Infect Dis, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Ctr Antimicrobial Resistance & Microbial Genet, Seoul, South Korea
来源
MICROBIOLOGY SPECTRUM | 2024年 / 12卷 / 08期
关键词
hVISA; vancomycin; treatment failure; risk factors; age; severity; minimal inhibitory concentration; MINIMUM INHIBITORY CONCENTRATIONS; METHICILLIN-RESISTANT; CLINICAL-FEATURES; INFECTIONS; STRAINS; HETERORESISTANCE; SUSCEPTIBILITY; DEFINITION; CRITERIA;
D O I
10.1128/spectrum.00333-24
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infection is increasing and is associated with vancomycin treatment failures. However, studies investigating the risk factors for treatment failure in hVISA infection are limited. Patients with hVISA bacteremia treated with vancomycin over 7 days between August 2008 and June 2020 were enrolled in this study. Clinical and microbiological characteristics were compared between vancomycin treatment failure and success groups to identify the risk factors for vancomycin treatment failure. Among the 180 patients with hVISA bacteremia, 102 patients treated with vancomycin over 7 days were included. Vancomycin treatment failed in 80 (78%) patients. Patients in the vancomycin treatment failure group were older (P < 0.001) and more frequently had solid cancer (P = 0.04) than those in the vancomycin treatment success group. Solid organ transplantation (SOT) was more frequent (P < 0.001) in the vancomycin treatment success group. The Charlson comorbidity index (P = 0.01) and Acute Physiology and Chronic Health Evaluation II scores (P < 0.001) were higher in the vancomycin treatment failure group. In multivariate analysis, independent risk factors for vancomycin treatment failure were old age and severity of bacteremia. SOT and vancomycin minimal inhibitory concentration (MIC) <= 1.0 mg/L using the broth microdilution (BMD) method were associated with successful vancomycin treatment. Old age and infection severity were independent risk factors for vancomycin treatment failure. Vancomycin MIC using the BMD method is an important risk factor for vancomycin treatment failure, and its use should be considered in hVISA bacteremia. IMPORTANCE In this study, we assessed the clinical and microbiological characteristics of heterogeneous vancomycin-intermediated Staphylococcus aureus (hVISA) bacteremia and identified risk factors for vancomycin treatment failure. We found that advanced age and severity of infection were independent risk factors for vancomycin treatment failure. On the other hand, solid organ transplantation and a low vancomycin minimal inhibitory concentration were associated with successful vancomycin treatment. This study highlights the importance of vancomycin minimal inhibitory concentration in hVISA bacteremia.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea
    Jung Wan Park
    Hyungmin Lee
    Jung Wook Kim
    Bongyoung Kim
    Scientific Reports, 9
  • [42] Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea
    Park, Jung Wan
    Lee, Hyungmin
    Kim, Jung Wook
    Kim, Bongyoung
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [43] Contribution of vraSR and graSR Point Mutations to Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus
    Cui, Longzhu
    Neoh, Hui-min
    Shoji, Mitsutaka
    Hiramatsu, Keiichi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) : 1231 - 1234
  • [44] An evaluation of 2.0 McFarland Etest method for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus
    Pongkumpai, Montri
    Trakulsomboon, Suwanna
    Suankratay, Chusana
    ASIAN BIOMEDICINE, 2010, 4 (01) : 141 - 145
  • [45] Comparative proteomic analysis of vancomycin-sensitive and vancomycin-intermediate resistant Staphylococcus aureus
    Hu, Jian
    Han, Xinjun
    Ma, Xiaoxue
    Chen, Xutao
    Zhou, Zhenping
    Peng, Peilan
    Yu, Zhao
    Hou, Yongzhi
    Han, Peiru
    Pang, Long
    Yang, Yali
    Xu, Jia
    Wu, Wenhui
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2024, 43 (01) : 203 - 208
  • [46] Comparative proteomic analysis of vancomycin-sensitive and vancomycin-intermediate resistant Staphylococcus aureus
    Jian Hu
    Xinjun Han
    Xiaoxue Ma
    Xutao Chen
    Zhenping Zhou
    Peilan Peng
    Zhao Yu
    Yongzhi Hou
    Peiru Han
    Long Pang
    Yali Yang
    Jia Xu
    Wenhui Wu
    European Journal of Clinical Microbiology & Infectious Diseases, 2024, 43 : 139 - 153
  • [47] Detection of heterogeneous vancomycin-intermediate Staphylococcus aureus: A preliminary report from south India
    Amberpet, Rajesh
    Sistla, Sujatha
    Sugumar, Madhan
    Nagasundaram, Niveditha
    Manoharan, Meerabai
    Parija, Subhash Chandra
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2019, 150 (02) : 194 - 198
  • [48] Successful treatment with daptomycin and ceftaroline of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) endocarditis: a case report
    Lin, Shang-Yi
    Hung, Wei-Chun
    Lo, Shih-Hao
    Tseng, Yi-Ting
    Lu, Po-Liang
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 27 : 335 - 336
  • [49] Low Prevalence of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates among Connecticut Veterans
    Fink, Susan L.
    Martinello, Richard A.
    Campbell, Sheldon M.
    Murray, Thomas S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (01) : 582 - 583
  • [50] Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus
    Cui, LZ
    Tominaga, E
    Neoh, HM
    Hiramatsu, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) : 1079 - 1082